

BMT for RDEB and JEB What have we learned, and what do we do next?



NEJM 2015

Jakub Tolar MD PhD University of Minnesota


How does BMT work in EB?



Donated cells circulate through the recipient's body and produce missing collagen

Donated cells engraft in bone marrow and produce healthy cells

Do bone marrow cells engraft in skin?




Kataoka Am J Pathol 2003

Fujita PNAS 2010

Does BMT work in EB?





Blood 2009

Should we do BMT for EB?

Systemic impacts of EB

- Internal surfaces
- Pain
- Itch
- Fibrosis
- Anemia
- Malnutrition
- Autoimmunity
- Dentition
- Kidney
- Heart



Is BMT reasonably safe?

- UMN Institutional Review Board
- External review boards

Protocol and patient safety



Colleen Delaney, MD



Gay Crooks, MD

Patient review









John McGrath, MD Hiros Alain Hovnanian, MD

Hiroshi Shimizu, MD, PhD
, MD Katsuto


Katsuto Tamai, MD, PhD


How do we do BMT for EB?

Adaptive Clinical Trial – 2007 to present Safety & effectiveness

- FDA Investigational New Drug IND 14166
- Clinical Trials (clinicaltrials.gov):
 - BMT for Severe EB (high dose): NCT00478244 closed
 - MSCs for Severe EB: NCT02581775
 - Skin grafting using BMT donor skin: NCT02670837
 - BMT for Severe EB (low dose/haplo donor): NCT0103355

Multiple measurements made at set timepoints: Engraftment: presence of donor cells in patient's skin







Visual and antibody identification of anchoring fibrils (electron microscopy)

Persistence: anchoring fibrils: 7 years after BMT

mAb185




LH24




Skin strength (blistering machine)
Correlation of skin strength with skin engraftment





Patient and parent report (iScorEB)

"Today he ate Chex, ice cream, melon, yogurt, popcorn, nachos and cheese, soft shell taco, a chocolate chip cookie, chips and salsa, and cereal with milk."







"He is standing, taking steps with support, and becoming active again."


Parent report of estimated impact on time and money

Conditioning	Transfusions	Hospital days
High dose	22.3	74.5
Low dose	6.3	38
	P=0.003	P=0.01

- 5-10 fold reduction in bandages
- Reduced time bandaging
- Fewer antibiotics and surgical interventions









Why does the trial change?

Overall 2-year survival = 75%



Should we do BMT for RDEB?




Should we do BMT for LAMA3 JEB?

1-year-old with LAMA3 JEB – high dose conditioning
Before transplant


1 year after transplant






















Should we do BMT for LAMA3 JEB?

10-year-old with *LAMA3* JEB – reduced intensity conditioning
Before transplant 2 years after transplant



50% donor in skin
BSA 75% before
< 50% after

Is HCT a cure for EB?

- No
- However, thus far...only clinical intervention shown to:
 - Correct the <u>systemic</u> disease pathology of RDEB
 - Have potential to improve <u>overall</u> quality of life

New BMT protocols for severe EB

1. Hematopoietic cells

Haploidentical grafts

2. Mesenchymal stromal cells


Three serial infusions


3. Epidermal cells

- Skin grafting from HCT donor
- Skin grafting from mosaic skin




Biomedical Moment







Cycle of learning



Combination therapy for RDEB



Cycle of learning





Outcome Measures

Follow-up and assessment over time


- 1. Biomarkers: C7, skin engraftment, anchoring fibrils
- 2. Skin strength
- 3. Wound healing, SCC
- 4. Time in hospital
- 5. Quality of life (iScorEB)

Cycle of learning





Cycle of learning



What more should we do for EB?

Cell projects

2009

BMT in RDEB mice

2010

BMT in people with RDEB (N=7)

2011

iPSCs from human RDEB cells

2013

iPSCs from human JEB cells

2014

iPSCs from human mosaic **RDEB** cells

2017

BMT in people with **RDEB (N=30)** (in review)

2009

2010

2011

2012

2013

2014

2015

2016

2017

2013

COL7A1 gene editing with **TALENS**

2016

C7 is regulated by mir-29


2016

COL7A1 gene editing with CRISPR/Cas9

2017

Col7a1 null mice for transfer of human cells

Gene projects



Collaborators and friends

John A. McGrath Katsuto Tamai Alain Hovnanian Mark Osborn Kristen Hook Leena Bruckner-Tuderman Jemma Mellerio Anne Lucky Elena Pope **Amy Paller** Michelle de Luca Francis Palisson Gabi Pohla-Gubo **Denis Roop** Peter Marinkovich Jouni Uitto



